Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Norgine’s Targaxan 550 receives Scottish NHS approval

Norgine’s Targaxan 550 receives Scottish NHS approval

18th September 2013

Norgine has announced that its drug Targaxan has been approved for Scottish NHS use as a treatment for overt hepatic encephalopathy.

The Scottish Medicines Consortium has ratified the therapy for use in the reduction in recurrence of episodes of overt hepatic encephalopathy in patients aged 18 years and older, based on positive findings from a six-month placebo-controlled study.

Hepatic encephalopathy is a serious and potentially fatal disease which develops when the liver ceases to function properly, resulting in a buildup of toxins in the blood that ultimately affects the brain.

It is estimated that more than 10,000 patients suffer from hepatic encephalopathy, with one-year survival rates standing at less than 50 percent.

Peter Martin, chief operating officer at Norgine, said: "This new treatment can reduce the treatment cost of cirrhotic patients by reducing the number of breakthrough episodes of hepatic encephalopathy and subsequent hospitalisations."

Targaxan 550 was developed in partnership with Alfa Wasserman and was originally made available in the UK in January 2013.ADNFCR-8000103-ID-801638796-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.